Although arguably premature as an overview, the progress of LIF-NP in nanomedicine is well underway and future major indications include the neurodegenerative diseases where LIF may reduce inflammatory pathogenesis and be prosurvival for neurons, for example in Parkinson's and Alzheimer's Diseases; also the retinopathies, where LIF's neurogenic and neuroprotective properties may reduce loss of vision by supporting the retinal pigment epithelium of the eye. The gene discussed is LIF; the disease is early-onset autosomal dominant Alzheimer disease.